Literature DB >> 21904302

Myriad decision reassures biotechs but diagnostics still murky.

Malorye Allison.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21904302     DOI： 10.1038/nbt0911-771

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  FDA transparency rules could hit small companies hardest.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2010-08       Impact factor: 54.908
  1 in total
  3 in total

1.  Foundation medicine.

Authors:  Michael Eisenstein
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908

2.  America Invents Act receives cautious welcome.

Authors:  Jeffrey L Fox
Journal:  Nat Biotechnol       Date:  2011-11-08       Impact factor: 54.908

3.  Industry reels as Prometheus falls and Myriad faces further reviews.

Authors:  Jeffrey L Fox
Journal:  Nat Biotechnol       Date:  2012-05-07       Impact factor: 54.908
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.